C
Catalyst Pharmaceuticals, Inc. (CPRX)
23.40
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
23.40
0.00 (0.00%)
Catalyst Pharmaceuticals, Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda kam uchraydigan kasalliklari bo'lgan bemorlar uchun dori vositalarini ishlab chiqish va tijoratlashtirishga qaratilgan. U lambert-eaton miyastenik sindromi (LEMS) bilan og'rigan bemorlarni davolash uchun Firdapse; fokal boshlanuvchi tutqanoqlarni, shuningdek tonik-klonik tutqanoqlarni davolash uchun ishlatiladigan postsinaptik ionotrop alfa-amino-3-gidroksi-5-metil-4-izoksazolpropion kislotasi glutamat retseptorining yangi, raqobatchi bo'lmagan selektiv antagonistini Fycompa; va Duchenne mushak distrofiyasini davolash uchun kortikosteroid bo'lgan AGAMREEni taklif etadi. Kompaniya BioMarin Pharmaceutical Inc. bilan litsenziyalash shartnomalariga; va jenerik Sabril planshetlarini ishlab chiqish va tijoratlashtirish bo'yicha Endo Ventures Limited bilan hamkorlik va litsenziyalash shartnomasiga ega. Catalyst Pharmaceuticals, Inc. 2002 yilda tashkil etilgan va Coral Gables, Florida shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer |
| Mr. Gregg Russo | Chief Human Resources Officer |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO |
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman |
| Mr. Richard John Daly M.B.A. | President, CEO & Director |
| Ms. Mary Coleman | VP & Head of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-19 | 8-K/A | d25173d8ka.htm |
| 2026-03-18 | 8-K | d111324d8k.htm |
| 2026-01-12 | 8-K | d62132d8k.htm |
| 2025-11-05 | 10-Q | cprx-20250930.htm |
| 2025-10-01 | 8-K | d118298d8k.htm |
| 2025-08-28 | 8-K/A | d40349d8ka.htm |
| 2025-08-25 | 8-K | d915025d8k.htm |
| 2025-08-07 | 8-K | d55613d8k.htm |
| 2025-08-06 | 8-K | d941750d8k.htm |
| 2025-08-04 | 8-K | d17349d8k.htm |